Dr. Michelle T. Long, MD, MSc is a physician scientist, hepatologist, and epidemiologist with an expertise in nonalcoholic fatty liver disease and the intersection between the liver and cardiometabolic disease. She has led numerous studies within the Framingham Heart Study evaluating the association between liver fat and fibrosis and cardiometabolic disease. Dr. Long is an Associate Professor of Medicine at Boston University School of Medicine. In July of 2022 shoe joined Novo Nordisk as the International Medical Vice President for NASH and Liver Diseases.